-+ 0.00%
-+ 0.00%
-+ 0.00%

On September 13, local time, GlaxoSmithKline issued a statement saying that the drug Jideytro achieved a clinically significant 94% objective remission rate in ROS1-positive non-small cell lung cancer patients who were not treated with tyrosine kinase inhibitors in the registered phase I/II Arros-1 trial.

Zhitongcaijing·09/14/2026 00:41:06
Listen to the news
On September 13, local time, GlaxoSmithKline issued a statement saying that the drug Jideytro achieved a clinically significant 94% objective remission rate in ROS1-positive non-small cell lung cancer patients who were not treated with tyrosine kinase inhibitors in the registered phase I/II Arros-1 trial.